{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:25Z","timestamp":1786120285690,"version":"build-2736575974"},"reference-count":124,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/ftd.0b013e31822fbf7c","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T13:49:03Z","timestamp":1317736143000},"page":"561-572","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic Drug Monitoring for Drugs Used in the Treatment of Substance-Related Disorders: Literature Review Using a Therapeutic Drug Monitoring Appropriateness Rating Scale"],"prefix":"10.1097","volume":"33","author":[{"given":"Sonja","family":"Br\u00fcnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe D","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Havemann-Reinecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/15622970801896390","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, Part 1: Alcoholism.","volume":"9","author":"Soyka","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/00003495-200969100-00003","article-title":"Varenicline: a novel pharmacotherapy for smoking cessation.","volume":"69","author":"Jimenez-Ruiz","year":"2009","journal-title":"Drugs"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0376-8716(00)00121-6","article-title":"Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.","volume":"61","author":"Eap","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2007-977712","article-title":"Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence.","volume":"40","author":"Ulrich","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1258\/acb.2010.010049","article-title":"Development of a clinically relevant liquid chromatography tandem mass spectrometry assay for 13 drugs of abuse in urine, designed to meet the needs of the service users.","volume":"47","author":"Duxbury","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00470582","article-title":"Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats.","volume":"78","author":"Glotzbach","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/0269881109105789","article-title":"Regional distribution of clomipramine and desmethylclomipramine in rat brain and peripheral organs on chronic clomipramine administration.","volume":"24","author":"Aitchison","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FTD.0b013e31817b1a95","article-title":"Therapeutic drug monitoring of voriconazole.","volume":"30","author":"Bruggemann","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00115-008-2471-9","article-title":"Expanding therapeutic reference ranges using dose-related reference ranges [in German].","volume":"79","author":"Haen","year":"2008","journal-title":"Nervenarzt"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/JCP.0b013e3181fc2cf1","article-title":"Partial compliance as determined from plasma levels of sertraline and its metabolite in depressed patients in primary care.","volume":"30","author":"Reis","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00115-007-2273-5","article-title":"Twenty-five years of lithium augmentation [in German].","volume":"78","author":"Bschor","year":"2007","journal-title":"Nervenarzt"},{"key":"R19-1-20210129","first-page":"724","article-title":"Seasonal variation in plasma levels of lithium in the Indian population: is there a need to modify the dose?","volume":"49","author":"Medhi","year":"2008","journal-title":"Singapore Med J"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2165\/00003088-200241090-00002","article-title":"Lithium in bipolar disorder: can drug concentrations predict therapeutic effect?","volume":"41","author":"Sproule","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R21-1-20210129","first-page":"471","article-title":"Lithium overdose causing non-convulsive status epilepticus--the importance of lithium levels and the electroencephalography in diagnosis.","volume":"13","author":"Yip","year":"2007","journal-title":"Hong Kong Med J"},{"key":"R22-1-20210129","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/00007691-200012000-00002","article-title":"Lithium poisoning from a poison control center perspective.","volume":"22","author":"Bailey","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R23-1-20210129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0006-3223(94)00243-V","article-title":"Caffeine withdrawal increases lithium blood levels.","volume":"37","author":"Mester","year":"1995","journal-title":"Biol Psychiatry"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.1985.133","article-title":"Effect of acute alcohol consumption on lithium kinetics.","volume":"38","author":"Anton","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0924-977X(99)00033-4","article-title":"Cytochrome P450 and therapeutic drug monitoring with respect to clozapine.","volume":"9","author":"Buur-Rasmussen","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"R26-1-20210129","first-page":"122","article-title":"Withdrawal from clozapine: the rebound phenomenon.","volume":"36","author":"Durst","year":"1999","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","article-title":"Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study.","volume":"21","author":"Gaertner","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R28-1-20210129","first-page":"87","article-title":"Le monitoring therapeutique de la clozapine: une necessite clinique.","volume":"41","author":"Rouleau","year":"2008","journal-title":"J Pharmactuel"},{"key":"R29-1-20210129","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003088-200342070-00001","article-title":"What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.","volume":"42","author":"Schulte","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-199732020-00001","article-title":"Will routine therapeutic drug monitoring have a place in clozapine therapy?","volume":"32","author":"Freeman","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1176\/ajp.153.12.1579","article-title":"Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.","volume":"153","author":"VanderZwaag","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R34-1-20210129","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00004714-200108000-00007","article-title":"CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia.","volume":"21","author":"Ozdemir","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R35-1-20210129","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0893-133X(02)00319-6","article-title":"Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia.","volume":"27","author":"Fabrazzo","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R37-1-20210129","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R38-1-20210129","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/bmj.3.5770.331","article-title":"Relationship between plasma level and therapeutic effect of nortriptyline.","volume":"3","author":"Asberg","year":"1971","journal-title":"Br Med J"},{"key":"R39-1-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jat\/13.5.303","article-title":"A nortriptyline death with unusually high tissue concentrations.","volume":"13","author":"Rohrig","year":"1989","journal-title":"J Anal Toxicol"},{"key":"R41-1-20210129","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/bmj.4.5686.764","article-title":"Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy.","volume":"4","author":"Alexanderson","year":"1969","journal-title":"Br Med J"},{"key":"R42-1-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004850-199801000-00002","article-title":"Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group.","volume":"13","author":"Demyttenaere","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"R43-1-20210129","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2165\/00002018-200629090-00001","article-title":"Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.","volume":"29","author":"Jaquenoud Sirot","year":"2006","journal-title":"Drug Saf"},{"key":"R44-1-20210129","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.","volume":"151","author":"Gillman","year":"2007","journal-title":"Br J Pharmacol"},{"key":"R45-1-20210129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database.","volume":"31","author":"Reis","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R46-1-20210129","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/ajp.146.7.911","article-title":"Elevated antidepressant plasma levels after addition of fluoxetine.","volume":"146","author":"Aranow","year":"1989","journal-title":"Am J Psychiatry"},{"key":"R47-1-20210129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0165-0327(85)90071-0","article-title":"Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in depressed inpatients.","volume":"8","author":"Simmons","year":"1985","journal-title":"J Affect Disord"},{"key":"R48-1-20210129","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0893-133X(02)00368-8","article-title":"A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.","volume":"27","author":"Mason","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R49-1-20210129","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-199835050-00001","article-title":"Clinical pharmacokinetics of acamprosate.","volume":"35","author":"Saivin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R50-1-20210129","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1517\/14656566.6.12.2103","article-title":"Acamprosate in the treatment of alcohol dependence.","volume":"6","author":"Mason","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"R51-1-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00213-009-1515-6","article-title":"The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial.","volume":"205","author":"Hammarberg","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"R52-1-20210129","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/FTD.0b013e3181e18638","article-title":"Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers.","volume":"32","author":"Hammarberg","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R54-1-20210129","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R55-1-20210129","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","article-title":"Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.","volume":"93","author":"Kuhlman","year":"1998","journal-title":"Addiction"},{"key":"R56-1-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0376-8716(98)00192-6","article-title":"Plasma concentrations of buprenorphine 24 to 72 hours after dosing.","volume":"55","author":"Chawarski","year":"1999","journal-title":"Drug Alcohol Depend"},{"key":"R57-1-20210129","first-page":"103","article-title":"Cardiopulmonary arrest and subsequent death after administration of buprenorphine in an elderly female: a case report.","volume":"3","author":"Fincham","year":"1989","journal-title":"J Geriatric Drug Ther"},{"key":"R58-1-20210129","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2217\/14622416.7.6.831","article-title":"Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.","volume":"7","author":"Du","year":"2006","journal-title":"Pharmacogenomics"},{"key":"R59-1-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R60-1-20210129","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1742-1241.1980.tb08143.x","article-title":"Buprenorphine: experience in an elderly population of 975 patients during a years monitored release.","volume":"34","author":"Harcus","year":"1980","journal-title":"Br J Clin Pract"},{"key":"R61-1-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/10550881003684814","article-title":"Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.","volume":"29","author":"Unger","year":"2010","journal-title":"J Addict Dis"},{"key":"R62-1-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.jcp.0000084023.22282.03","article-title":"Neurochemical and psychotropic effects of bupropion in healthy male subjects.","volume":"23","author":"Gobbi","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R63-1-20210129","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R65-1-20210129","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.","volume":"30","author":"Spina","year":"2008","journal-title":"Clin Ther"},{"key":"R66-1-20210129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14622200110042852","article-title":"Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation.","volume":"3","author":"Johnston","year":"2001","journal-title":"Nicotine Tob Res"},{"key":"R67-1-20210129","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1176\/ajp.147.12.1690","article-title":"Therapeutic drug monitoring of bupropion.","volume":"147","author":"Preskorn","year":"1990","journal-title":"Am J Psychiatry"},{"key":"R68-1-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1517\/14740338.1.4.303","article-title":"Zyban--is there a cause for concern?","volume":"1","author":"Tracey","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"R69-1-20210129","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/jat\/32.2.192","article-title":"A fatal case of bupropion (Zyban) overdose.","volume":"32","author":"Mercerolle","year":"2008","journal-title":"J Anal Toxicol"},{"key":"R70-1-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10865-005-3663-4","article-title":"Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback.","volume":"28","author":"Schmitz","year":"2005","journal-title":"J Behav Med"},{"key":"R71-1-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008571-200404000-00002","article-title":"Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.","volume":"14","author":"Hesse","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R72-1-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00007691-200206000-00021","article-title":"Serum concentration of chlormethiazole and therapeutic effect in acute alcohol withdrawal syndrome: an open clinical trial.","volume":"24","author":"Ulrich","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R75-1-20210129","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF00563077","article-title":"The pharmacokinetics of chlormethiazole following intravenous administration in the aged.","volume":"10","author":"Nation","year":"1976","journal-title":"Eur J Clin Pharmacol"},{"key":"R76-1-20210129","first-page":"771","article-title":"The management of alcohol withdrawal using chlormethiazole.","volume":"30","author":"Morgan","year":"1995","journal-title":"Alcohol Alcohol"},{"key":"R77-1-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000067729","article-title":"Symptom-triggered versus standard chlormethiazole treatment of inpatient alcohol withdrawal: clinical implications from a chart analysis.","volume":"9","author":"Lange-Asschenfeldt","year":"2003","journal-title":"Eur Addict Res"},{"key":"R78-1-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.1992.tb03309.x","article-title":"The pharmacology and toxicology of disulfiram and its metabolites.","volume":"369","author":"Petersen","year":"1992","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R79-1-20210129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.1992.tb03310.x","article-title":"A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites.","volume":"369","author":"Johansson","year":"1992","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R80-1-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0009-2797(92)90082-V","article-title":"Hepatocyte cytotoxicity induced by various hepatotoxins mediated by cytochrome P-450IIE1: protection with diethyldithiocarbamate administration.","volume":"81","author":"Lauriault","year":"1992","journal-title":"Chem Biol Interact"},{"key":"R81-1-20210129","first-page":"1212","article-title":"Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation.","volume":"22","author":"Madan","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"R82-1-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2125.2002.01522.x","article-title":"Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.","volume":"53","author":"Frye","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R83-1-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0773.1992.tb00423.x","article-title":"Clinical responses in relation to blood acetaldehyde levels.","volume":"70","author":"Johnsen","year":"1992","journal-title":"Pharmacol Toxicol"},{"key":"R84-1-20210129","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.1984.213","article-title":"Elimination kinetics of disulfiram in alcoholics after single and repeated doses.","volume":"36","author":"Faiman","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"R85-1-20210129","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/alcalc\/agm062","article-title":"Compliance with aftercare treatment, including disulfiram, and effect on outcome in alcohol-dependent patients.","volume":"42","author":"Neto","year":"2007","journal-title":"Alcohol Alcohol"},{"key":"R86-1-20210129","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1530-0277.1985.tb05531.x","article-title":"The disulfiram-alcohol reaction: factors determining and potential tests predicting severity.","volume":"9","author":"Beyeler","year":"1985","journal-title":"Alcohol Clin Exp Res"},{"key":"R87-1-20210129","first-page":"461","article-title":"Distribution of acetaldehyde in human blood: effects of ethanol and treatment with disulfiram.","volume":"28","author":"Helander","year":"1993","journal-title":"Alcohol Alcohol"},{"key":"R88-1-20210129","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.amjopharm.2007.03.006","article-title":"Risks of combined alcohol\/medication use in older adults.","volume":"5","author":"Moore","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"R89-1-20210129","first-page":"2378","article-title":"Liver damage attributed to the use of disulfiram [in German].","volume":"139","author":"Kerkhof","year":"1995","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R90-1-20210129","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R91-1-20210129","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"R92-1-20210129","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm00266a009","article-title":"Urinary metabolites of dl-methadone in maintenance subjects.","volume":"16","author":"Sullivan","year":"1973","journal-title":"J Med Chem"},{"key":"R93-1-20210129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00004714-200104000-00016","article-title":"Cytochrome P450 2D6 genotype and methadone steady-state concentrations.","volume":"21","author":"Eap","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R94-1-20210129","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R95-1-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000019006","article-title":"On the usefulness of therapeutic drug monitoring of methadone.","volume":"6","author":"Eap","year":"2000","journal-title":"Eur Addict Res"},{"key":"R96-1-20210129","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00228-007-0327-z","article-title":"An in vitro approach to potential methadone metabolic-inhibition interactions.","volume":"63","author":"Bomsien","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R97-1-20210129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archpsyc.55.1.89","article-title":"High interindividual variability of methadone enantiomer blood levels to dose ratios.","volume":"55","author":"Eap","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"R98-1-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10550880903436010","article-title":"Methadone maintenance dosing guideline for opioid dependence, a literature review.","volume":"29","author":"Fareed","year":"2010","journal-title":"J Addict Dis"},{"key":"R99-1-20210129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/0959523021000023171","article-title":"Methadone dose and post-mortem blood concentration.","volume":"21","author":"Caplehorn","year":"2002","journal-title":"Drug Alcohol Rev"},{"key":"R100-1-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1037\/1064-1297.10.1.39","article-title":"Heroin craving and drug use in opioid-maintained volunteers: effects of methadone dose variations.","volume":"10","author":"Greenwald","year":"2002","journal-title":"Exp Clin Psychopharmacol"},{"key":"R101-1-20210129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03256276","article-title":"Interindividual variability of methadone response: impact of genetic polymorphism.","volume":"12","author":"Li","year":"2008","journal-title":"Mol Diagn Ther"},{"key":"R102-1-20210129","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1049909107312597","article-title":"Methadone.","volume":"25","author":"Chhabra","year":"2008","journal-title":"Am J Hosp Palliat Care"},{"key":"R104-1-20210129","first-page":"CD001333","article-title":"Naltrexone maintenance treatment for opioid dependence.","volume":"2","author":"Kirchmayer","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"R107-1-20210129","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1211\/0022357045020","article-title":"Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol.","volume":"56","author":"Breyer-Pfaff","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"R108-1-20210129","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2165\/00003088-198308040-00004","article-title":"Clinical pharmacokinetics of narcotic agonist-antagonist drugs.","volume":"8","author":"Bullingham","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"R109-1-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0376-8716(98)00098-2","article-title":"Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment in drug addicts.","volume":"52","author":"Ferrari","year":"1998","journal-title":"Drug Alcohol Depend"},{"key":"R110-1-20210129","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00216-009-3301-z","article-title":"Determination of naltrexone and 6beta-naltrexol in human blood: comparison of high-performance liquid chromatography with spectrophotometric and tandem-mass-spectrometric detection.","volume":"396","author":"Brunen","year":"2009","journal-title":"Anal Bioanal Chem"},{"key":"R111-1-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002130100909","article-title":"Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.","volume":"159","author":"Comer","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"R112-1-20210129","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cpt1976203315","article-title":"Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.","volume":"20","author":"Verebey","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"R113-1-20210129","first-page":"906","article-title":"Naltrexone biotransformation and incidence of subjective side effects: a preliminary study.","volume":"21","author":"King","year":"1997","journal-title":"Alcohol Clin Exp Res"},{"key":"R115-1-20210129","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2125.2000.00281.x","article-title":"Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.","volume":"50","author":"Porter","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R116-1-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0006-8993(83)90023-9","article-title":"Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat.","volume":"289","author":"Bardo","year":"1983","journal-title":"Brain Res"},{"key":"R117-1-20210129","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1360-0443.2008.02345.x","article-title":"Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.","volume":"103","author":"Kranzler","year":"2008","journal-title":"Addiction"},{"key":"R118-1-20210129","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0091270006292624","article-title":"Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.","volume":"46","author":"Faessel","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R120-1-20210129","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","article-title":"Inheritance and drug response.","volume":"348","author":"Weinshilboum","year":"2003","journal-title":"N Engl J Med"},{"key":"R122-1-20210129","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-0447.2000.tb10948.x","article-title":"Compliance with antidepressant therapy and antidepressant discontinuation symptoms.","volume":"403","author":"Demyttenaere","year":"2000","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R123-1-20210129","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(01)06417-0","article-title":"Costeffectiveness of diagnostic tests.","volume":"358","author":"Mushlin","year":"2001","journal-title":"Lancet"},{"key":"R124-1-20210129","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"R125-1-20210129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-2007-979583","article-title":"Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high-performance liquid chromatography. Data from a prospective clinical trial.","volume":"28","author":"Schulz","year":"1995","journal-title":"Pharmacopsychiatry"},{"key":"R126-1-20210129","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/nedt.2006.2.4.445","article-title":"Acamprosate: a new tool in the battle against alcohol dependence.","volume":"2","author":"Wright","year":"2006","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R127-1-20210129","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jat\/20.6.369","article-title":"Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.","volume":"20","author":"Kuhlman","year":"1996","journal-title":"J Anal Toxicol"},{"key":"R128-1-20210129","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0149-2918(99)80005-8","article-title":"Pharmacokinetics and pharmacodynamics of clomethiazole after oral and rectal administration in healthy subjects.","volume":"21","author":"Ratz","year":"1999","journal-title":"Clin Ther"},{"key":"R130-1-20210129","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/clpt.1980.219","article-title":"Buprenorphine kinetics.","volume":"28","author":"Bullingham","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"R131-1-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.0306-5251.2003.01850.x","article-title":"Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients.","volume":"56","author":"Zingmark","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R132-1-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00228-003-0598-y","article-title":"Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole.","volume":"59","author":"Centerholt","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"R133-1-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1742-7843.2009.00432.x","article-title":"The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.","volume":"105","author":"Moody","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R134-1-20210129","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0009-9236(99)90090-5","article-title":"Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.","volume":"65","author":"Dyer","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R135-1-20210129","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1081\/DDC-100102181","article-title":"Comparative bioavailability study of a generic naltrexone tablet preparation.","volume":"25","author":"Yuen","year":"1999","journal-title":"Drug Dev Ind Pharm"},{"key":"R136-1-20210129","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.2042-7158.1990.tb07028.x","article-title":"Plasma protein binding of disulfiram and its metabolite diethylthiocarbamic acid methyl ester.","volume":"42","author":"Johansson","year":"1990","journal-title":"J Pharm Pharmacol"},{"key":"R137-1-20210129","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/clpt.1982.217","article-title":"Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein.","volume":"32","author":"Abramson","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"R138-1-20210129","doi-asserted-by":"crossref","first-page":"862","DOI":"10.15288\/jsad.2007.68.862","article-title":"Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence.","volume":"68","author":"Dunbar","year":"2007","journal-title":"J Stud Alcohol Drugs"},{"key":"R139-1-20210129","first-page":"127","article-title":"Metabolism of a disulfiram metabolite, S-methyl N,N-diethyldithiocarbamate, by flavin monooxygenase in human renal microsomes.","volume":"29","author":"Pike","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R140-1-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/dmd.105.006767","article-title":"Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.","volume":"34","author":"Obach","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R141-1-20210129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R142-1-20210129","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0095-4543(21)01100-3","article-title":"Management of depression in the elderly.","volume":"16","author":"Williams","year":"1989","journal-title":"Prim Care"},{"key":"R143-1-20210129","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0168-8278(97)80355-8","article-title":"Effect of liver cirrhosis on the systemic availability of naltrexone in humans.","volume":"27","author":"Bertolotti","year":"1997","journal-title":"J Hepatol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e31822fbf7c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:22:19Z","timestamp":1786047739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201110000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31822fbf7c","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}